Navigation Links
Pharmacyclics Announces Dr. Ahmed Hamdy as New Chief Medical Officer

SUNNYVALE, Calif., March 16 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today the appointment of Dr. Ahmed Hamdy as its new Chief Medical Officer. Dr. Hamdy most recently served as Therapeutic Area Head at Elan Pharmaceuticals responsible for gastroenterology and autoimmune clinical development. Dr. Hamdy's experience ranges across all clinical development phases (9 Phase I, 3 Phase II, 8 Phase III and 3 Phase IV trials). He has a track record of delivering a number of INDs and NDAs (5 INDs, 1 ANDA, 1 sNDA and 1 NDA). In the past, Dr. Hamdy was responsible for more than 37 clinical trials where he authored and oversaw the development of multiple clinical development plans, protocols and study reports in numerous therapeutic areas (oncology, urology, autoimmune, anemia, pain and cardiovascular).

Dr. Hamdy has also served as the General Medicine Therapeutic Area Head at PDL BioPharma from February 2006 to June 2008, where he was responsible for the clinical development activities for Cardene IV(R) premixed bag formulations, which was approved in 2008 and the development of Ularitide(R) for the treatment of congestive heart failure. From September 2004 to February 2006, Dr. Hamdy was a medical director at Johnson and Johnson/ALZA where he participated in NDA submissions for OROS Hydromorphone (Jurnista(R)) for moderate to severe pain approved in Europe 2006. From October 2000 to August 2004, Dr. Hamdy was a Senior Principal Scientist at Watson Pharmaceuticals where he participated in an ANDA for testosterone gel for the treatment of hypogonadism that was approved 2005. He also participated in multiple INDs in oncology and autoimmune diseases leading to successful phase I and phase II programs. Dr. Hamdy received his M.D. (M.B.B.Ch) from Cairo University, Egypt.

Said Dr. Glenn Rice, COO and President: "Dr. Hamdy has deep and broad industry experience and has shown time and time again that he can deliver high quality clinical studies in a timely manner and successfully represent these studies to the FDA. He is also a former Olympic crew team member for Egypt, a sport that demands exacting team work, precision, strength and endurance. These qualities have guided his professional career and are qualities that will serve him well in this leadership position at Pharmacyclics. We are pleased to have him on board to guide our extensive clinical portfolio of best in class and first in class cancer and autoimmune therapeutics."

About Pharmacyclics

Pharmacyclics(R) is committed to creating and developing novel pharmaceutical products that treat serious unmet medical needs in oncology and autoimmune diseases. Its deep and broad pipeline includes four innovative drug candidates that are currently under clinical development. The Company is headquartered in Silicon Valley (Sunnyvale) California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at

NOTE: Other than statements of historical fact, the statements made in this press release about enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to estimate accurately the amount of cash to be used to fund operations over the next 12 months, our ability to obtain future financing and fund the product development of our pipeline; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2007 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmacyclics Receives Nasdaq Notification
2. Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
3. Pharmacyclics Reports Third Quarter 2008 Financial Results
4. Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results
5. Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
6. Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
7. Announces Q4 2008 Results
8. NxStage Announces Credit Facility Amendment
9. DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008
10. CSA Medical, Inc. Announces Launch of New Web Site for Spray Cryotherapy
11. Alzheimers Disease Neuroimaging Initiative announces completion of genome-wide analysis
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug ... need to integrate dose form selection in early phase drug development. The first ... supporting and bringing together the UK’s emerging life sciences companies, corporate partners, and ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is ... 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an ... every day excited to rebuild lives and it’s an honor to have served all ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/26/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact ... and reliability. , The new Q-Suite 6 platform is based on the latest Java ... into a specific piece of software for many key components of the suite. Much ...
(Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
(Date:11/25/2015)... Asia -based venture ... and the New Investors will make a direct equity ... private placement. The financing will help IOPtima to continue ... in the treatment of glaucoma, as well as to ... system with the U.S. Food and Drug Administration, commencing ...
(Date:11/25/2015)... , November 25, 2015 Developmental, commercial, ... in boosting the profitability of pharmaceutical products, says ... and regulatory/legal strategies all play a key ... says GBI Research . --> ... a key role in boosting the profitability of pharmaceutical products, ...
Breaking Medicine Technology: